Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome

Martin T Christian, Andrew P Maxted, Martin T Christian, Andrew P Maxted

Abstract

The use of corticosteroids in the treatment of steroid-sensitive nephrotic (SSNS) syndrome in children has evolved surprisingly slowly since the ISKDC consensus over 50 years ago. From a move towards longer courses of corticosteroid to treat the first episode in the 1990s and 2000s, more recent large, well-designed randomized controlled trials (RCTs) have unequivocally shown no benefit from an extended course, although doubt remains whether this applies across all age groups. With regard to prevention of relapses, daily ultra-low-dose prednisolone has recently been shown to be more effective than low-dose alternate-day prednisolone. Daily low-dose prednisolone for a week at the time of acute viral infection seems to be effective in the prevention of relapses but the results of a larger RCT are awaited. Recently, corticosteroid dosing to treat relapses has been questioned, with data suggesting lower doses may be as effective. The need for large RCTs to address the question of whether corticosteroid doses can be reduced was the conclusion of the authors of the recent corticosteroid therapy for nephrotic syndrome in children Cochrane update. This review summarizes development in thinking on corticosteroid use in SSNS and makes suggestions for areas that merit further scrutiny.

Trial registration: ClinicalTrials.gov NCT03970577.

Keywords: Adrenal suppression; Corticosteroid; Minimal change disease; Nephrotic syndrome; Relapse; Steroid sensitive.

Conflict of interest statement

Martin Christian is the chief investigator for the PREDNOS 2 study and is currently a member of the IPNA clinical practice recommendations on steroid-sensitive nephrotic syndrome (SSNS).

© 2021. IPNA.

References

    1. Shakespeare, Romeo and Juliet, Act 2, Scene 2.
    1. Arneil GC. The nephrotic syndrome. Pediatr Clin N Am. 1971;18:547–559. doi: 10.1016/S0031-3955(16)32565-2.
    1. Hodson E, Knight J, Willis N, Craig J. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2002;2:CD001533. doi: 10.1002/14651858.cd001533.
    1. Hodson EM, Knight JF, Willis NS, Craig JC (2005) Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. Jan 25;(1):CD001533. 10.1002/14651858.CD001533.pub3
    1. Hahn D, Hodson EM, Willis NS, Craig JC (2015) Corticosteroid therapy for nephrotic syndrome in children (Review). Cochrane Database Syst Rev. 10.1002/
    1. Hahn D, Samuel SM, Willis NS, Narelle S, Craig JC, Hodson EM (2020) Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 10.1002/14651858.CD001533.pub6
    1. KDIGO (2012) Clinical practice guideline for glomerulonephritis. Chapter 3: steroid-sensitive nephrotic syndrome in children. Kidney Int Supp 2, 143:163–171. 10.1038/kisup.2012.12
    1. (1979) Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of “Arbetsgemeinschaft für Pädiatrische Nephrologie.” Lancet 24:401–403
    1. (1988) Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Lancet 331:380–383.
    1. Ueda N, Chihara M, Kawaguchi S, Niinomi Y, Nonoda T, Matsumoto J, Ohnishi M, Yasaki T. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. J Pediatr. 1988;112:122–126. doi: 10.1016/S0022-3476(88)80136-7.
    1. Hodson EM, Craig JC, Willis NS. Evidence-based management of steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2005;20:1523–1530. doi: 10.1007/s00467-005-1968-8.
    1. Deschênes G, Vivarelli M, Peruzzi L. Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries. Eur J Pediatr. 2017;176:647–654. doi: 10.1007/s00431-017-2891-2.
    1. Teeninga N, Kist-van Holthe JE, Van Rijswijk N, de Mos NI, Hop WCJ, Wetzels JFM, van der Heijden AJ, Nauta J. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol. 2013;24:149–159. doi: 10.1681/ASN.2012070646.
    1. Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, Ishikura K, Hataya H, Honda M, Ito S, Shima Y, Kaito H, Nozu K, Nakamura H, Igarashi T, Ohashi Y, Iijima K. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int. 2015;87:227–232. doi: 10.1038/ki.2014.260.
    1. Sinha A, Saha A, Kumar M, Sharma S, Afzal K, Mehta A, Kalaivani M, Hari P, Bagga A. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence The course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int. 2015;87:217–224. doi: 10.1038/ki.2014.240.
    1. Webb NJA, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Deeks JJ, Wheatley K, Ives NJ. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. BMJ. 2019;365:l1800. doi: 10.1136/bmj.l1800.
    1. Webb NJA, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Wheatley K, Ives NJ. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT. Health Technol Assess (Rockv) 2019;23:1–108. doi: 10.3310/hta23260.
    1. Andersen RF, Thrane N, Noergaard K, Rytter L, Jespersen B, Rittig S. Early age at debut is a predictor of steroid-dependent and frequent relapsing nephrotic syndrome. Pediatr Nephrol. 2010;25:1299–1304. doi: 10.1007/s00467-010-1537-7.
    1. Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, Hayashi S, Ohta K, Momoi T, Ohshima Y, Suganuma N, Mayumi M. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis. 2003;41:1155–1162. doi: 10.1016/S0272-6386(03)00346-9.
    1. Alangari AA. Corticosteroids in the treatment of acute asthma. Ann Thorac Med. 2014;9:187–192. doi: 10.4103/1817-1737.140120.
    1. (2010) Body surface area for adjustment of drug dose. Drug Ther Bull 48:33–36
    1. Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, Wigfall D, Miles P, Powell L, Lin JJ, Trachtman H, Greenbaum LA. Management of childhood onset nephrotic syndrome. Pediatrics. 2009;124:747–757. doi: 10.1542/peds.2008-1559.
    1. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098. doi: 10.1056/NEJM198710223171717.
    1. Du Bois D, Du Bois E. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med. 1916;17:863–871. doi: 10.1001/archinte.1916.00080130010002.
    1. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: A height-weight formula validated in infants, children, and adults. J Pediatr. 1978;93:62–66. doi: 10.1016/S0022-3476(78)80601-5.
    1. Feber J, Al-Matrafi J, Farhadi E, Vaillancourt R, Wolfish N. Prednisone dosing per body weight or body surface area in children with nephrotic syndrome - is it equivalent? Pediatr Nephrol. 2009;24:1027–1031. doi: 10.1007/s00467-008-1089-2.
    1. Hirano D, Fujinaga S. Two dosing regimens for steroid therapy in nephrotic syndrome. Pediatr Nephrol. 2014;29:325. doi: 10.1007/s00467-013-2417-8.
    1. Emma F, Montini G, Gargiulo A. Equations to estimate prednisone dose using body weight. Pediatr Nephrol. 2019;34:685–688. doi: 10.1007/s00467-018-4127-8.
    1. Saadeh SA, Baracco R, Jain A, Kapur G, Mattoo TK, Valentini RP. Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference? Pediatr Nephrol. 2011;26:2167–2171. doi: 10.1007/s00467-011-1961-3.
    1. Basu B, Bhattacharyya S, Barua S, Naskar A, Roy B. Efficacy of body weight vs body surface area-based prednisolone regimen in nephrotic syndrome. Clin Exp Nephrol. 2020;24:622–629. doi: 10.1007/s10157-020-01875-y.
    1. Raman V, Krishnamurthy S, Harichandrakumar KT. Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial. Pediatr Nephrol. 2016;31:595–604. doi: 10.1007/s00467-015-3285-1.
    1. Sharkey I, Boddy AV, Wallace H, Mycroft J, Hollis R, Picton S. Body surface area estimation in children using weight alone: Application in paediatric oncology. Br J Cancer. 2001;85:23–28. doi: 10.1054/bjoc.2001.1859.
    1. Mehls O, Hoyer PF. Dosing of glucocorticosteroids in nephrotic syndrome. Pediatr Nephrol. 2011;26:2095–2098. doi: 10.1007/s00467-011-1993-8.
    1. Groeneweg FL, Karst H, de Kloet ER, Joëls M. Rapid non-genomic effects of corticosteroids and their role in the central stress response. J Endocrinol. 2011;209:153–167. doi: 10.1530/JOE-10-0472.
    1. Schijvens AM, ter Heine R, de Wildt SN, Schreuder MF. Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. Pediatr Nephrol. 2019;34:389–403. doi: 10.1007/s00467-018-3929-z.
    1. Jusko WJ, Rose JQ. Monitoring prednisone and prednisolone. Ther Drug Monit. 1980;2:169–176. doi: 10.1097/00007691-198004000-00011.
    1. Noone DG, Iijima K, Parekh R. Seminar: Idiopathic nephrotic syndrome in children. Lancet. 2018;392:61–74. doi: 10.1016/S0140-6736(18)30536-1.
    1. Mocan H, Erduran E, Karagüzel G. High dose methylprednisolone therapy in nephrotic syndrome. Indian J Pediatr. 1999;66:171–174. doi: 10.1007/BF02761198.
    1. Imbasciati E, Gusmano R, Edefonti A, Zucchelli P, Pozzi C, Grassi C, Della Volpe M, Perfumo F, Petrone P, Picca M, Appiani AC, Pasquali S, Ponticelli C. Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome. Br Med J (Clin Res Ed) 1985;291:1305–1308. doi: 10.1136/bmj.291.6505.1305.
    1. Deschênes G, Dossier C, Hogan J. Treating the idiopathic nephrotic syndrome: are steroids the answer? Pediatr Nephrol. 2019;34:777–785. doi: 10.1007/s00467-018-3963-x.
    1. Shenoy M, Plant ND, Lewis MA, Bradbury MG, Lennon R, Webb NJA. Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome. Pediatr Nephrol. 2010;25:899–903. doi: 10.1007/s00467-009-1417-1.
    1. Dossier C, Delbet JD, Boyer O, Dossier C, Delbet JD, Boyer O, Daoud P, Mesples B, Pellegrino B, See H, Benoist G, Chace A, Larakeb A, Hogan J, Deschênes G. Five-year outcome of children with idiopathic nephrotic syndrome: the NEPHROVIR population-based cohort study. Pediatr Nephrol. 2019;34:671–678. doi: 10.1007/s00467-018-4149-2.
    1. Pasini A, Benetti E, Conti G, Ghio L, Lepore M, Massella L, Molino D, Peruzzi L, Emma F, Fede C, Trivelli A, Maringhini S, Materassi M, Messina G, Montini G, Murer L, Pecoraro C, Pennesi M. The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part i - Diagnosis and treatment of the first episode and the first relapse. Ital J Pediatr. 2017;43:41. doi: 10.1186/s13052-017-0356-x.
    1. Hari P, Bagga A, Mantan M. Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr. 2004;41:993–1000.
    1. Colquitt JL, Kirby J, Green C, Cooper K, Trompeter RS. The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review. Health Technol Assess (Rockv) 2007;11:iii-iv, ix-xi, 1-93. doi: 10.3310/hta11210.
    1. Rocci M, Assael B, Appiani AC, Edefonti A, Jusko WJ. Effect on nephrotic syndrome on absorption and disposition of prednisolone in children. Int J Pediatr Nephrol. 1982;3:159–166.
    1. Gatti G, Perucca E, Frigo G, Notarangelo LD, Barberis L, Martini A. Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. Br J Clin Pharmacol. 1984;17:423–431. doi: 10.1111/j.1365-2125.1984.tb02367.x.
    1. Faure C, André J, Pelatan C, Munck A, Giraud M, Cèzard JP, Jacqz-Aigrain E. Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. Eur J Clin Pharmacol. 1998;54:555–560. doi: 10.1007/s002280050512.
    1. Broyer M, Terzi F, Lehnert A, Gagnadoux MF, Guest G, Niaudet P. A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome. Pediatr Nephrol. 1997;11:418–422. doi: 10.1007/s004670050308.
    1. Singhal R, Pandit S, Dhawan N. Deflazacort versus prednisolone: Randomized controlled trial in treatment of children with idiopathic nephrotic syndrome. Iran J Pediatr. 2015;25:e510. doi: 10.5812/ijp.510.
    1. Aljebab F, Alanazi M, Choonara I, Conroy S. Observational study on the palatability and tolerability of oral prednisolone and oral dexamethasone in children in Saudi Arabia and the UK. Arch Dis Child. 2018;103:83–88. doi: 10.1136/archdischild-2017-312697.
    1. Lucas-Bouwman ME, Roorda RJ, Jansman FGA, Brand PLP. Crushed prednisolone tablets or oral solution for acute asthma? Arch Dis Child. 2001;84:347–348. doi: 10.1136/adc.84.4.347.
    1. Haslund-Krog SS, Schmidt M, Mathot R, Jensen AK, Jørgensen IM, Holst H. Pharmacokinetics of prednisolone in children: An open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease. BMJ Paediatr Open. 2019;3:1–7. doi: 10.1136/bmjpo-2019-000520.
    1. Elzouki AY, Jaiswal OP. Long-term, small dose prednisonetherapy in frequently relapsing nephrotic syndrome of childhood: effect on remission, statural growth, obesity, and infection rate. Clin Pediatr (Phila) 1988;27:387–392. doi: 10.1177/000992288802700807.
    1. Srivastava RN, Vasudev AS, Bagga A, Sunderam KR. Long-term, low-dose prednisolone therapy in frequently relapsing nephrotic syndrome. Pediatr Nephrol. 1992;6:247–250. doi: 10.1007/BF00878359.
    1. Yadav M, Sinha A, Khandelwal P, Hari P, Bagga A. Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Pediatr Nephrol. 2019;34:829–835. doi: 10.1007/s00467-018-4071-7.
    1. Alwadhi RK, Mathew JL, Rath B. Clinical profile of children with nephrotic syndrome not on glucorticoid therapy, but presenting with infection. J Paediatr Child Health. 2004;40:28–32. doi: 10.1111/j.1440-1754.2004.00285.x.
    1. Arun S, Bhatnagar S, Menon S, Savita S, Hari P, Bagga A. Efficacy of zinc supplements in reducing relapses in steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2009;24:1583–1586. doi: 10.1007/s00467-009-1170-5.
    1. MacDonald NE, Wolfish N, McLaine P, Phipps P, Rossier E. Role of respiratory viruses in exacerbations of primary nephrotic syndrome. J Pediatr. 1986;108:378–382. doi: 10.1016/S0022-3476(86)80876-9.
    1. Moorani KN, Khan KMA, Ramzan A. Infections in children with nephrotic syndrome. J Coll Physicians Surg Pak. 2003;13:337–339.
    1. Gulati A, Sinha A, Sreenivas V, Math A, Hari P, Bagga A. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6:63–69. doi: 10.2215/CJN.01850310.
    1. Mattoo TK, Mahmoud MA. Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome. Nephron. 2000;85:343–345. doi: 10.1159/000045684.
    1. Abeyagunawardena AS, Trompeter RS. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. Arch Dis Child. 2008;93:226–228. doi: 10.1136/adc.2007.116079.
    1. Abeyagunawardena AS, Thalgahagoda RS, Dissanayake PV, Abeyagunawardena S, Illangasekera YA, Karunadasa UI, Trompeter RS. Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome. Pediatr Nephrol. 2017;32:1377–1382. doi: 10.1007/s00467-017-3640-5.
    1. Webb NJA, Frew E, Brettell EA, Milford DV, Bockenhauer D, Saleem MA, Christian M, Hall AS, Koziell A, Maxwell H, Hegde S, Finlay ER, Gilbert RD, Booth J, Jones C, McKeever K, Cook W, Ives NJ. Short course daily prednisolone therapy during an upper respiratory tract infection in children with relapsing steroid-sensitive nephrotic syndrome (PREDNOS 2): Protocol for a randomised controlled trial. Trials. 2014;15:147. doi: 10.1186/1745-6215-15-147.
    1. Achenbach T (2001) Achenbach system of empirically based assessment (ASEBA) Manual for the Child Behaviour Checklist pre-school (1.5–5 year), 2000 and school (6–18 year). Research Centre for Children Youth and Families, Burlington, VT
    1. Choonara IA, Heney D, Meadow SR. Low dose prednisolone in nephrotic syndrome. Arch Dis Child. 1989;64:610–611. doi: 10.1136/adc.64.4.610.
    1. Warshaw BL, Hymes LC. Daily single-dose and daily reduced-dose prednisone therapy for children with the nephrotic syndrome. Pediatrics. 1989;83:694–699. doi: 10.1542/peds.83.5.694.
    1. Raja K, Parikh A, Webb H, Hothi D. Use of a low-dose prednisolone regimen to treat a relapse of steroid-sensitive nephrotic syndrome in children. Pediatr Nephrol. 2017;32:99–105. doi: 10.1007/s00467-016-3458-6.
    1. Fujinaga S, Sakuraya K. Initial prednisolone dosing for the first relapse of steroid-sensitive nephrotic syndrome in Japanese children. Pediatr Nephrol. 2018;33:2205–2206. doi: 10.1007/s00467-018-4064-6.
    1. Borovitz Y, Alfandary H, Haskin O, Levi S, Shulamit K, Davidovits M, Dagan A. Lower prednisone dosing for steroid-sensitive nephrotic syndrome relapse: a prospective randomized pilot study. Eur J Pediatr. 2019;179:279–283. doi: 10.1007/s00431-019-03506-5.
    1. Sheikh S, Mishra K, Kumar M. Low versus conventional dose prednisolone for nephrotic syndrome relapses: randomised-controlled, non-inferiority trial. Pediatr Nephrol. 2019;34:1980.
    1. Gargiulo A, Massella L, Ruggiero B, Ravà L, Ciofi degli Atti M, Materassi M, Lugani F, Benetti E, Morello W, Molino D, Mattozzi F, Pennesi M, Maringhini S, Pasini A, Gianoglio B, Pecoraro D, Montini G, Murer L, Ghiggeri GM, Romagnani P, Vivarelli M, Emma F. Results of the PROPINE randomized controlled study suggest tapering of prednisone treatment for relapses of steroid sensitive nephrotic syndrome is not necessary in children. Kidney Int. 2021;99:475–483. doi: 10.1016/j.kint.2020.09.024.
    1. Schijvens AM, Dorresteijn EM, Roeleveld N, ter Heine R, van Wijk JAE, Bouts AHM, Keijzer-Veen MG, van de Kar NCAJ, van den Heuvel LPWJ, Schreuder MF. REducing STEroids in Relapsing Nephrotic syndrome: The RESTERN study-protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study. BMJ Open. 2017;7:e018148. doi: 10.1136/bmjopen-2017-018148.
    1. Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of short-course oral corticosteroids in children. Arch Dis Child. 2016;101:365–370. doi: 10.1136/archdischild-2015-309522.
    1. Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of long-course oral corticosteroids in children. Arch Dis Child. 2016;101:365–370. doi: 10.1136/archdischild-2015-309522.
    1. Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Nakanishi K, Matsuyama T, Ito S, Hamasaki Y, Yata N, Ando T, Iijima K, Honda M. Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. Pediatr Nephrol. 2014;30:459–468. doi: 10.1007/s00467-014-2955-8.
    1. Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med. 2004;351:868–875. doi: 10.1056/NEJMoa040367.
    1. Wetzsteon RJ, Shults J, Zemel BS, Gupta PU, Burnham JM, Herskovitz RM, Howard KM, Leonard MB. Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome. J Bone Miner Res. 2009;24:503–513. doi: 10.1359/jbmr.081101.
    1. Tsampalieros A, Gupta P, Denburg MR, Shults J, Zemel BS, Mostoufi-Moab S, Wetzsteon RJ, Whitehead KM, Leonard MB. Glucocorticoid effects on changes in bone mineral density and cortical structure in childhood nephrotic syndrome. J Bone Miner Res. 2013;28:480–488. doi: 10.1002/jbmr.1785.
    1. Ribeiro D, Zawadynski S, Pittet LF, Chevalley T, Giradin E, Parvex P. Effect of glucocorticoids on growth and bone mineral density in children with nephrotic syndrome. Eur J Pediatr. 2015;174:911–917. doi: 10.1007/s00431-014-2479-z.
    1. Kyrieleis HAC, Löwik MM, Pronk I, Cruysberg HRM, Kremer JAM, Oyen WJG, van den Heuvel BLP, Wetzels JFM, Levtchenko EN. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol. 2009;4:1593–1600. doi: 10.2215/CJN.05691108.
    1. Skrzypczyk P, Pańczyk-Tomaszewska M, Roszkowska-Blaim M, Wawer Z, Bienias B, Zajgzkowska M, Kilis-Pstrusinska K, Jakubowska A, Szczepaniak M, Pawlak-Bratkowska M, Tkaczyk M. Long-term outcomes in idiopathic nephrotic syndrome: From childhood to adulthood. Clin Nephrol. 2014;81:166–173. doi: 10.5414/CN108044.
    1. Hall AS, Thorley G, Houtman PN. The effects of corticosteroids on behavior in children with nephrotic syndrome. Pediatr Nephrol. 2003;18:1220–1223. doi: 10.1007/s00467-003-1295-x.
    1. Mishra OP, Basu B, Upadhyay SK, Prasad R, Schaefer F. Behavioural abnormalities in children with nephrotic syndrome. Nephrol Dial Transplant. 2010;25:2537–2541. doi: 10.1093/ndt/gfq097.
    1. Upadhyay A, Mishra OP, Prasad R, Upadhyay SK, Schaefer F. Behavioural abnormalities in children with new-onset nephrotic syndrome receiving corticosteroid therapy: results of a prospective longitudinal study. Pediatr Nephrol. 2016;31:233–238. doi: 10.1007/s00467-015-3216-1.
    1. Soliday E, Grey S, Lande MB. Behavioral effects of corticosteroids in steroid-sensitive nephrotic syndrome. Pediatrics. 1999;104:e51–e51. doi: 10.1542/peds.104.4.e51.
    1. Mehta M, Bagga A, Pande P, Bajaj G, Srivastava RN. Behavior problems in nephrotic syndrome. Indian Pediatr. 1995;32:1281–1286.
    1. Achenbach T, Edelbrock C (1983) Manual for the child behavior checklist and revised behavior profile. University of Vermont Department of Psychiatry
    1. Leisti S, Koskimies O. Risk of relapse in steroid-sensitive nephrotic syndrome: Effect of stage of post-prednisone adrenocortical suppression. J Pediatr. 1983;103:553–557. doi: 10.1016/S0022-3476(83)80582-4.
    1. Bowden SA, Connolly AM, Kinnett K, Zeitler PS. Management of adrenal insufficiency risk after long-term systemic glucocorticoid therapy in Duchenne muscular dystrophy : clinical practice recommendations. J Neuromusc Dis. 2019;6:31–41. doi: 10.3233/JND-180346.
    1. Rensen N, Gemke RJBJ, van Dalen EC, Rotteveel J, Kaspers GJL (2017) Hypothalamic-pituitary-adrenal ( HPA ) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia (Review). 10.1002/
    1. Ahmet A, Benchimol EI, Goldbloom EB, Barkey JL. Adrenal suppression in children treated with swallowed fluticasone and oral viscous budesonide for eosinophilic esophagitis. Allergy Asthma Clin Immunol. 2016;12:49. doi: 10.1186/s13223-016-0154-9.
    1. Hawcutt DB, Jorgensen AL, Wallin N, Thompson B, Peak M, Lacy D, Newland P, Didi M, Couriel J, Blair J, Pirmohamed M, Smyth RL. Adrenal responses to a low-dose short synacthen test in children with asthma. Clin Endocrinol (Oxf) 2015;82:648–656. doi: 10.1111/cen.12655.
    1. Hawcutt DB, Jorgensen AL, Wallin N, Thompson B, Peak M, Lacy D, Newland P, Didi M, Couriel J, Blair J, Pirmohamed M, Smyth RL. Erratum: Adrenal responses to a low-dose short synacthen test in children with asthma. Clin Endocrinol (Oxf) 2016;82:648–656. doi: 10.1111/cen.12655.
    1. Miloslavsky EM, Naden RP, Bijlsma JWJ, Brogan PA, Brown ES, Brunetta P, Buttgereit F, Choi HK, DiCaire JF, Gelfand JM, Heaney LG, Lightstone E, Lu N, Murrell DF, Petri M, Rosenbaum JT, Saag KS, Urowitz MB, Winthrop KL, Stone JH. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2016;76:543–546. doi: 10.1136/annrheumdis-2016-210002.
    1. Brogan P, Naden R, Ardoin S, Cooper JC, De Benedetti F, DiCaire JF, Eleftheriou D, Feldman BM, Goldin J, Karol SE, Miloslavsky EM, Price-Kuehne F, Skuse D, Stratakis CA, Webb N, Stone JH (2018) Development of a Pediatric Glucocorticoid Toxicity Index. Arthritis. Rheumatol 70(suppl 10)
    1. Nephrotic girl. . Accessed 27 Sep 2020
    1. Tong A, Samuel S, Zappitelli M, Dart A, Furth S, Eddy A, Groothoff J, Webb NJA, Yap H-K, Bockenhauer D, Sinha A, Alexander SI, Goldstein SL, Gipson DS, Hanson CS, Evangelidis N, CroweS HT, Hemmelgarn BR, Manns B, Gill J, Tugwell P, Van Biesen W, Wheeler DC, Winkelmayer WC, Craig JC. Standardised Outcomes in Nephrology-Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease. Trials. 2016;17:401. doi: 10.1186/s13063-016-1528-5.
    1. Hanson CS, Gutman T, Craig JC, Bernays S, Raman G, Zhang Y, James LJ, Ralph AF, Ju A, Manera KE, Teixeira-Pinto A, Viecelli AK, Alexander SI, Blydt-Hansen TD, Dionne J, McTaggart S, Michael M, Walker A, Carter S, Wenderfer SE, Winkelmayer WC, Bockenhauer D, Dart A, Eddy AA, Furth SL, Gipson DS, Goldstein SL, Groothoff J, Samuel S, Sinha A, Webb NJA, Yap H-K, Zappitelli M, Currier H, Tong A. Identifying important outcomes for young people with CKD and their caregivers: a nominal group technique study. Am J Kidney Dis. 2019;74:82–94. doi: 10.1053/j.ajkd.2018.12.040.
    1. Uwaezuoke SN. The role of novel biomarkers in childhood idiopathic nephrotic syndrome: a narrative review of published evidence. Int J Nephrol Renovasc Dis. 2017;10:123–128. doi: 10.2147/IJNRD.S131869.
    1. Vivarelli M, Moscaritolo E, Tsalkidis A, Massella L, Emma F. Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome. J Pediatr. 2010;156:965–971. doi: 10.1016/j.jpeds.2009.12.020.
    1. Harambat J, Godron A, Ernould S, Rigothier C, Llanas B, Leroy S. Prediction of steroid-sparing agent use in childhood idiopathic nephrotic syndrome. Pediatr Nephrol. 2013;28:631–638. doi: 10.1007/s00467-012-2365-8.
    1. Nakanishi K, Iijima K, Ishikura K, Hataya H, Nakazato H, Sasaki S, Honda M, Yoshikawa N. Two-year outcome of the ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome. Clin J Am Soc Nephrol. 2013;8:756–762. doi: 10.2215/CJN.09010912.
    1. Mishra OP, Abhinay A, Mishra RN, Prasad R, Pohl M. Can we predict relapses in children with idiopathic steroid-sensitive nephrotic syndrome? J Trop Pediatr. 2013;59:358–364. doi: 10.1093/tropej/fmt029.
    1. Colucci M, Cascioli S, Vivarelli M, Serafinelli J, Emma F, Vivarelli M. B cell phenotype in pediatric idiopathic nephrotic syndrome. Pediatr Nephrol. 2018;34:177–181. doi: 10.1007/s00467-018-4095-z.
    1. Cuzzoni E, De Iudicibus S, Franca R, Stocco G, Lucafò M, Pelin M, Favretto D, Pasini A, Montini G, Decorti G. Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome. Pharmacogenomics. 2015;16:1631–1648. doi: 10.2217/pgs.15.101.
    1. Leisti S, Koskimies O, Rapola J, Hallman N, Perheentupa J, Vilska J. Association of post-medication hypocortisolism with early first relapse of idiopathic nephrotic syndrome. Lancet. 1977;2:795–796. doi: 10.1016/S0140-6736(77)90726-7.
    1. Leisti S, Vilska J, Hallman N. Adrenocortical insufficiency and relapsing in the idiopathic nephrotic syndrome of childhood. Pediatrics. 1977;60:334–342. doi: 10.1542/peds.60.3.334.
    1. Abeyagunawardena AS, Hindmarsh P, Trompeter RS. Adrenocortical suppression increases the risk of relapse in nephrotic syndrome. Arch Dis Child. 2007;92:585–588. doi: 10.1136/adc.2006.108985.
    1. Leisti S, Koskimies O, Perheentupa J, Vilska J, Hallman N. Idiopathic nephrotic syndrome : prevention of early relapse. Br Med J (Clin Res Ed) 1978;1:892. doi: 10.1136/bmj.1.6117.892.
    1. Blair J, Lancaster G, Titman A, Peak M, Newlands P, Collingwood C, Chesters C, Moorcroft T, Wallin N, Hawcutt D, Gardner C, Didi M, Lacy D, Couriel J. Early morning salivary cortisol and cortisone, and adrenal responses to a simplified low-dose short Synacthen test in children with asthma. Clin Endocrinol (Oxf) 2014;80:376–383. doi: 10.1111/cen.12302.
    1. Tarshish P, Tobin JN, Bernstein J, Edelmann CM. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol. 1997;8:769–776. doi: 10.1681/ASN.V85769.
    1. Hoyer PF, Brodehl J. Initial treatment of idiopathic nephrotic syndrome in children: Prednisone versus prednisone plus cyclosporine A: A prospective, randomized trial. J Am Soc Nephrol. 2006;17:1151–1157. doi: 10.1681/ASN.2005090922.
    1. Veltkamp F, Khan DH, Reefman C, Veissi S, van Oers HA, Levtchenko E, Mathôt RAA, Florquin S, van Wijk JAE, Schreuder MF, Haverman L, Bouts AHM (2019) Prevention of relapses with levamisole as adjuvant therapy in children with a first episode of idiopathic nephrotic syndrome: Study protocol for a double blind, randomised placebo-controlled trial (the LEARNS study). BMJ Open 9. 10.1136/bmjopen-2018-027011
    1. Mühlig AK, Lee JY, Kemper MJ, Kronbichler A, Yang JW, Lee JM, Shin JI, Oh J. Levamisole in children with idiopathic nephrotic syndrome: clinical efficacy and pathophysiological aspects. J Clin Med. 2019;8:860. doi: 10.3390/jcm8060860.
    1. Boyer O, Moulder JK, Grandin L, Somers MJG. Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome. Pediatr Nephrol. 2008;23:575–580. doi: 10.1007/s00467-007-0708-7.
    1. Madani A, Isfahani ST, Rahimzadeh N, Fereshtehnejad SM, Hoseini R, Moghtaderi M, Mohseni P, Ataiee N. Effect of levamisole in steroid-dependent nephrotic syndrome. Iran J Kidney Dis. 2010;4:292–296.
    1. Elmas AT, Tabel Y, Elmas ÖN. Short- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome. Int Urol Nephrol. 2013;45:1047–1055. doi: 10.1007/s11255-012-0241-x.
    1. Ehren R, Benz MR, Doetsch J, Fichtner A, Gellermann J, Haffner D, Höcker B, Hoyer PF, Kästner B, Kemper MJ, Konrad M, Luntz S, Querfeld U, Sander A, Toenshoff B, Weber LT (2018) Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil versus prednisone: protocol for a randomised, controlled, multicentre trial (INTENT study). BMJ Open. 10.1136/bmjopen-2018-024882
    1. Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F. Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome a randomized clinical trial. JAMA Pediatr. 2018;172:757–764. doi: 10.1001/jamapediatrics.2018.1323.
    1. Nagano C, Sako M, Kamei K, Ishikura K, Nakamura H, Nakanishi K, Omori T, Nozu K, Iijima K. Study protocol: Multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial) BMC Nephrol. 2019;20:293. doi: 10.1186/s12882-019-1470-3.
    1. Zhang B, Liu T, Wang W, Zhang X, Fan S, Liu Z, Liu Z, Wu X. A prospective randomly controlled clinical trial on azithromycin therapy for induction treatment of children with nephrotic syndrome. Eur J Pediatr. 2014;173:509–515. doi: 10.1007/s00431-013-2192-3.
    1. Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, Hui NK, Boyer O, Saleem MA, Feltran L, Müller-Deile J, Becker JU, Cano F, Xu H, Lim YN, Smoyer W, Anochie I, Nakanishi K, Hodson E, Haffner D. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35:1529–1561. doi: 10.1007/s00467-020-04519-1.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe